Insmed

Forecast & Rating23 analysts currently cover Insmed, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $200.05, about 55.7% upside from the current price of $128.46. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 55.1% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Insmed closely still see room for the stock to rise. Data as of Aug 18, 2026; for reference only and not investment advice.